UCL’s Novel Approach to Research in Biologically-Relevant Models
News Mar 19, 2014
Cellectricon will co-host a webinar with top researchers at University College London (UCL). The webinar will explore the use of primary cells as a biologically-relevant model for biomedical research, and highlight the new high-throughput techniques and phenotypic screening approaches that are used by UCL to investigate cellular processes in such cells.
The paradigm shift which proposes the use of primary cell types, rather than traditional transformed cell lines, provides a more physiologically accurate view and could help reduce the current high attrition rate in drug discovery programmes.
Offering participants a rare opportunity to hear first-hand from leading researchers, the webinar, entitled ‘Novel approaches for the study of cellular processes in biologically-relevant model systems’, will take place on March 27, 11am-12pm EDT.
To register, please visit www.cellecticon.com/events.
Participants will hear from Dr Robin Ketteler, Group Leader, and Dr Catia Andreassi, Senior Scientist, at the MRC Laboratory for Molecular Cell Biology, UCL, who will provide listeners with an expert insight into the mechanisms of axonal mRNA transport, a vital process for the maintenance of precise neuronal networks in the brain.
The session will go on to reveal how Dr Ketteler’s team are using combinatorial approaches to investigate cellular regulation mechanisms in primary neurons, and how these methods have enabled the group to identify a novel regulatory element that directs mRNA localization and translation.
Attendees of this webinar will gain an educational and eye-opening overview of new techniques that can be used successfully to drive biomedical research in biologically-relevant models.
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Novel Microplate 3D Bioprinting Platform for Engineering Muscle and Tendon TissuesNews
There is a strong need for medication that treats age-related degenerative muscle and tendon diseases. A critical bottleneck in the discovery and development of novel drugs for skeletal muscle is the lack of efficient and robust functional in vitro assays for compound screening. Researchers describe the development of a novel screening platform with automated production of 3D muscle- and tendon–like tissues using 3D bioprinting.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE